Case Type: Mergers & Acquisitions

OncBioMune Pharmaceuticals, Inc. (OBMP) related to its merger with Avant Diagnostics, Inc. Under the terms of the agreement, OBMP will acquire all of the outstanding assets of Avant diagnostic in exchange for a number of shares of its Series D-1 Preferred Convertible Stock, with current shareholders of OBMP expected to own 45.5% of the common … Read more

Broadway Financial Corporation (BFYC) related to its merger with CFBanc Corporation. Under the terms of the agreement, CFBanc shareholders will receive 13.626 shares of Broadway Financial common stock for each share of CFBanc common stock they own, resulting in Broadway Financial stockholders owning 52.5% and CFBanc shareholders owning 47.5% of the combined company.

Proteostasis Therapeutics, Inc. (PTI) related to its merger with Yumanity Therapeutics. Under the terms of the agreement, Proteostasis will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of Proteostasis common stock, with existing Proteostasis shareholders expected to own approximately 32.5% of the combined company.

Cancer Genetics, Inc. (CGIX) related to its merger with StemoniX. Under the terms of the agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of its common stock, with current shareholders of Cancer Genetics expected to own 22% of the common stock of the … Read more

Yintech Investment Holdings Limited (YIN) related to its sale to a group of rollover shareholders that includes members of Yintech’s management and board of directors. Under the terms of the agreement, holders of Yintech shares will receive $0.365 in cash per share, and holders of Yintech American depository shares will receive $7.30 in cash per … Read more

Momenta Pharmaceuticals, Inc. (MNTA) related to its sale to Johnson & Johnson. Under the terms of the agreement, MNTA shareholders will receive $52.50 in cash for each share of MNTA stock they own.

NTN Buzztime, Inc. (NTN) related to its merger with Brooklyn ImmunoTherapeutics LLC. Under the terms of the agreement, the members of Brooklyn ImmunoTherapeutics LLC will collectively own 94.08% of the outstanding common stock of the combined company and NTN Buzztime stockholders will collectively own 5.92% of the outstanding common stock of the combined company.

Churchill Capital Corp III (CCXX) related to its proposed merger with MultiPlan, Inc. Under the terms of the agreement, Churchill Capital shareholders will retain ownership of less than 20% of the combined company.

Principia Biopharma Inc. (PRNB) related to its sale to Sanofi. Under the terms of the agreement, PRNB shareholders will receive $100.00 in cash for each share of PRNB stock they own.

MVC Capital, Inc. (MVC) related to its sale to Barings BDC, Inc. Under the terms of the agreement, MVC Capital shareholders will receive 0.94024 shares of Barings BDC stock and $0.39492 in cash for each share of MVC Capital stock owned.